PMID

Data

Article Title

Organization

Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.

University of Tennessee Health Science Center

Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.

Ono Pharmaceutical

Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.

Ono Pharmaceutical

Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor.

The University of Tennessee Health Science Center

Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists.

Hoffmann-La Roche

Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists.

The University of Utah

Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.

F. Hoffmann-La Roche

Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.

Amgen

Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.

University of Tennessee Health Science Center

Structure-based drug design identifies novel LPA3 antagonists.

The University of Memphis

Identification of non-lipid LPA3 antagonists by virtual screening.

The University of Memphis

Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists.

Ajinomoto

Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.

The University of Utah

Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.

University of Tennessee Health Science Center

Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.

University of Tennessee Health Science Center

Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA

Universidad Complutense De Madrid

A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.

University of Virginia

Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.

Oxford University

Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.

University of Virginia

Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546.

Biogen

Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.

X-Chem

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA

Universidad Complutense De Madrid

Lysophosphatidic Acid Receptor 1 Antagonists for the Treatment of Fibrosis.

Therachem Research Medilab

Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

University of Virginia

Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia.

Ono Pharmaceutical

Design of potent selective zinc-mediated serine protease inhibitors.

Arris